866-997-4948(US-Canada Toll Free)

Neurofibromatoses - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 71 Pages

Neurofibromatoses - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses (Genetic Disorders) pipeline landscape.

Neurofibromatosis (commonly abbreviated NF; neurofibromatosis type 1 is also known as von Recklinghausen disease) is a genetically-inherited disorder in which the nerve tissue grows tumors (neurofibromas) that may be benign or may cause serious damage by compressing nerves and other tissues. The disorder affects all neural crest cells (Schwann cells, melanocytes and endoneurial fibroblasts). Cellular elements from these cell types proliferate excessively throughout the body, forming tumors; melanocytes also function abnormally in this disease, resulting in disordered skin pigmentation and caf au lait spots. The tumors may cause bumps under the skin, colored spots, skeletal problems, pressure on spinal nerve roots, and other neurological problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neurofibromatoses (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase 0, Preclinical and Discovery stages are 3, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Neurofibromatoses (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Neurofibromatoses (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neurofibromatoses (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neurofibromatoses (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neurofibromatoses (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Neurofibromatoses Overview 7
Therapeutics Development 8
Pipeline Products for Neurofibromatoses - Overview 8
Pipeline Products for Neurofibromatoses - Comparative Analysis 9
Neurofibromatoses - Therapeutics under Development by Companies 10
Neurofibromatoses - Therapeutics under Investigation by Universities/Institutes 11
Neurofibromatoses - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Neurofibromatoses - Products under Development by Companies 14
Neurofibromatoses - Products under Investigation by Universities/Institutes 15
Neurofibromatoses - Companies Involved in Therapeutics Development 16
Alexion Pharmaceuticals Inc 16
Arno Therapeutics Inc 17
AstraZeneca Plc 18
Betta Pharmaceuticals Co Ltd 19
Celldex Therapeutics Inc 20
Lixte Biotechnology Holdings Inc 21
Novartis AG 22
Plex Pharmaceuticals Inc 23
Neurofibromatoses - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AR-42 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
asfotase alfa - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CDX-0158 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
everolimus - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
FRAX-597 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
icotinib hydrochloride - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
LB-201 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
LB-205 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
OS-342 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
selumetinib sulfate - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecules for Neurofibromatoses Type I - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
VAL-0524 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Neurofibromatoses - Dormant Projects 67
Neurofibromatoses - Discontinued Products 68
Neurofibromatoses - Product Development Milestones 69
Featured News & Press Releases 69
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables
Number of Products under Development for Neurofibromatoses, H2 2016 8
Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Neurofibromatoses - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 16
Neurofibromatoses - Pipeline by Arno Therapeutics Inc, H2 2016 17
Neurofibromatoses - Pipeline by AstraZeneca Plc, H2 2016 18
Neurofibromatoses - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 19
Neurofibromatoses - Pipeline by Celldex Therapeutics Inc, H2 2016 20
Neurofibromatoses - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 21
Neurofibromatoses - Pipeline by Novartis AG, H2 2016 22
Neurofibromatoses - Pipeline by Plex Pharmaceuticals Inc, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Neurofibromatoses - Dormant Projects, H2 2016 67
Neurofibromatoses - Discontinued Products, H2 2016 68

List of Figures
Number of Products under Development for Neurofibromatoses, H2 2016 8
Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Top 10 Targets, H2 2016 25
Number of Products by Stage and Top 10 Targets, H2 2016 25
Number of Products by Mechanism of Actions, H2 2016 27
Number of Products by Stage and Mechanism of Actions, H2 2016 27
Number of Products by Routes of Administration, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 29
Number of Products by Molecule Types, H2 2016 31
Number of Products by Stage and Molecule Types, H2 2016 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *